Eileen Manabat, MD
Anesthesiology · Philadelphia, PANPI 1548380124
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,606 of the $5,442 with a category attached, or 84.6%. It is spread thinly across 31 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,253 and has fallen 70.1% since, to $673 in 2025. Among anesthesiology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biodelivery Sciences International, Inc.$879
- Vertos Medical, Inc.$638
- Nevro Corp.$638
- Si-bone, Inc.$326
- Abbott$306
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$246
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$75014%
- Food & beverage$4,60685%
- Education$862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biodelivery Sciences International, Inc. | 19 | $879 |
| Vertos Medical, Inc. | 17 | $638 |
| Nevro Corp. | 18 | $638 |
| Si-bone, Inc. | 7 | $326 |
| Abbott | 9 | $306 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $246 |
| MDD US Operations, LLC | 19 | $211 |
| Saluda Medical Americas, Inc. | 3 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $167 |
| Stryker | 3 | $165 |
| Collegium Pharmaceutical, Inc. | 22 | $152 |
| Zyla Life Sciences, Inc. | 16 | $149 |
| Assertio Therapeutics, Inc. | 10 | $139 |
| Globus Medical | 4 | $132 |
| Pfizer | 14 | $125 |
| Daiichi Sankyo Inc. | 9 | $123 |
| MML US, Inc. | 1 | $115 |
| Arbor Pharmaceuticals, Inc. | 6 | $112 |
| Boston Scientific | 4 | $99 |
| Medtronic(2 entities) | 5 | $96 |
| AstraZeneca(2 entities) | 6 | $88 |
| Biotronik NRO, Inc. | 4 | $86 |
| Sentynl Therapeutics, Inc. | 6 | $74 |
| Avanos Medical | 1 | $46 |
| Kaleo, Inc. | 3 | $41 |
| International Rehabilitative Sciences, Inc | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Pacira Therapeutics, Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| Pernix Therapeutics Holdings, Inc. | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BELBUCA$750
- mild Device Kit$301
- Senza Spinal Cord Stimulation System$140
- Senza$138
- Evoke$136
- ReActiv8$115
How this compares
$5,442 in reported general payments places this provider in the 95th percentile of 2,015 anesthesiology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 21 | $78,999 |
| BelbucaBuprenorphine Hcl | 94 | $64,303 |
| Buprenorphine | 104 | $22,638 |
| HorizantGabapentin Enacarbil | 19 | $18,902 |
| OxycontinOxycodone Hcl | 48 | $17,899 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 431 | $12,223 |
| Oxycodone Hcl | 522 | $10,260 |
| Lidocaine | 89 | $7,325 |
| Gabapentin | 396 | $4,651 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 215 | $4,079 |
| Diclofenac Sodium | 49 | $3,880 |
| Xtampza ErOxycodone Myristate | 11 | $3,569 |
| Pregabalin | 169 | $3,338 |
| Nucynta ErTapentadol Hcl | 11 | $3,313 |
| Chlorzoxazone | 23 | $3,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er | $152 | $71,184116 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $112 | $18,90219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,015 anesthesiology providers in Pennsylvania.
Other anesthesiology in Philadelphia
- Lee FleisherPhiladelphia$659K
- Eugene ViscusiPhiladelphia$398K
- Michael ScottPhiladelphia$250K
- Joshua AtkinsPhiladelphia$55K
- Jacob RaphaelPhiladelphia$32K
- Armen VoskeridjianPhiladelphia$26K
- Eleazar MorrisPhiladelphia$19K
- Brian MalonePhiladelphia$15K
- Rebecca BarnettPhiladelphia$14K
- Michael WilliamsPhiladelphia$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.